<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01403818</url>
  </required_header>
  <id_info>
    <org_study_id>1941-CL-0074</org_study_id>
    <nct_id>NCT01403818</nct_id>
  </id_info>
  <brief_title>A Study to Assess the Effect of ASP1941 and Mitiglinide on Their Plasma Concentration</brief_title>
  <official_title>Pharmacokinetic Study of ASP1941 -A Pharmacokinetic Study to Assess Drug-Drug Interaction Between ASP1941 and Mitiglinide Calcium Hydrate</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Astellas Pharma Inc</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Astellas Pharma Inc</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study is to assess the pharmacokinetic interaction between ASP1941 and Mitiglinide
      calcium hydrate in healthy volunteers.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This will be a randomized, open label, four group, two-way crossover design study to assess
      the effect of drug interaction between ASP1941 and Mitiglinide calcium hydrate on the
      pharmacokinetics of them after separate and concomitant administration to healthy non-elderly
      adult male subjects.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>June 2011</start_date>
  <completion_date type="Actual">August 2011</completion_date>
  <primary_completion_date type="Actual">August 2011</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Pharmacokinetics of ASP1941 and Mitiglinide calcium hydrate assessed by its plasma concentration change</measure>
    <time_frame>For up to 72 hours after each administration</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Safety assessed by incidence of adverse event, vital signs, 12-lead ECG and laboratory tests</measure>
    <time_frame>For up to 10 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetics of the metabolites of ASP1941 assessed by its plasma concentration change</measure>
    <time_frame>For 72 hours after ASP1941 administration</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">60</enrollment>
  <condition>Healthy</condition>
  <condition>Pharmacokinetics of ASP1941</condition>
  <condition>Pharmacokinetics of Mitiglinide</condition>
  <arm_group>
    <arm_group_label>Part 1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subjects will receive &quot;ASP1941 alone&quot; and &quot;ASP1941 + Mitiglinide calcium hydrate&quot; in different orders.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Part 2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subjects will receive &quot;Mitiglinide calcium hydrate alone&quot; and &quot;ASP1941 + Mitiglinide calcium hydrate&quot; in different orders.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>ASP1941</intervention_name>
    <description>oral</description>
    <arm_group_label>Part 1</arm_group_label>
    <arm_group_label>Part 2</arm_group_label>
    <other_name>ipragliflozin</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Mitiglinide calcium hydrate</intervention_name>
    <description>oral</description>
    <arm_group_label>Part 1</arm_group_label>
    <arm_group_label>Part 2</arm_group_label>
    <other_name>Glufast</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Healthy as judged by the investigator/subinvestigator based on the results of physical
             examinations and laboratory tests

          -  Body weight ; ≥50.0 kg, &lt;80.0 kg

          -  Body Mass Index ; ≥17.6, &lt;26.4 kg/m2

          -  Written informed consent has been obtained

        Exclusion Criteria:

          -  Received any investigational drugs within 120 days before the screening assessment

          -  Donated 400 mL of whole blood within 90 days, 200 mL of whole blood within 30 days, or
             d components within 14 days before the screening assessment

          -  Received medication within 7 days before hospital admission

          -  A deviation from the assessment criteria of physical examinations or laboratory tests
             at screening or upon admission

          -  History of drug allergies

          -  With renal, hepatic, gastrointestinal, heart, cerebrovascular or respiratory diseases

          -  Previous treatment with ASP1941
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>44 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Use Central Contact</last_name>
    <role>Study Chair</role>
    <affiliation>Astellas Pharma Inc</affiliation>
  </overall_official>
  <location>
    <facility>
      <address>
        <city>Kantou</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Japan</country>
  </location_countries>
  <verification_date>October 2011</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>July 25, 2011</study_first_submitted>
  <study_first_submitted_qc>July 26, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 27, 2011</study_first_posted>
  <last_update_submitted>October 10, 2011</last_update_submitted>
  <last_update_submitted_qc>October 10, 2011</last_update_submitted_qc>
  <last_update_posted type="Estimate">October 12, 2011</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>ASP1941</keyword>
  <keyword>ipragliflozin</keyword>
  <keyword>Mitiglinide calcium hydrate</keyword>
  <keyword>Drug-Drug interaction</keyword>
  <keyword>Pharmacokinetics</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Calcium, Dietary</mesh_term>
    <mesh_term>Mitiglinide</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

